269 related articles for article (PubMed ID: 10731782)
1. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer.
Maxon HR
Q J Nucl Med; 1999 Dec; 43(4):313-23. PubMed ID: 10731782
[TBL] [Abstract][Full Text] [Related]
2. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
Gerard SK; Dam HQ
Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
[No Abstract] [Full Text] [Related]
3. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
4. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
5. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
7. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer.
Samuel AM; Rajashekharrao B; Shah DH
J Nucl Med; 1998 Sep; 39(9):1531-6. PubMed ID: 9744337
[TBL] [Abstract][Full Text] [Related]
9. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
Muratet JP; Daver A; Minier JF; Larra F
J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
11. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
12. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
13. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic scintigraphy and effectiveness of 131I radioiodine therapy in differentiated thyroid carcinoma (DTC)].
Bałdys-Waligórska A; Buziak-Bereza M; Huszno B; Wilczak A
Endokrynol Pol; 2006; 57(4):380-5. PubMed ID: 17006840
[TBL] [Abstract][Full Text] [Related]
15. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
[TBL] [Abstract][Full Text] [Related]
16. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
Mäenpää H
Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
[TBL] [Abstract][Full Text] [Related]
17. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
Fatourechi V; Hay ID; Mullan BP; Wiseman GA; Eghbali-Fatourechi GZ; Thorson LM; Gorman CA
Thyroid; 2000 Jul; 10(7):573-7. PubMed ID: 10958309
[TBL] [Abstract][Full Text] [Related]
18. Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake.
Oyen WJ; Mudde AH; van den Broek WJ; Corstens FH
J Nucl Med; 1995 Apr; 36(4):613-5. PubMed ID: 7699452
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
20. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
